Review

Poly(A) polymerase (PAP) diversity in gene expression – Star-PAP vs canonical PAP

Rakesh S. Laishram *

Cancer Research Program, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram 695014, India

Article info

Article history:
Received 7 February 2014
Revised 2 May 2014
Accepted 15 May 2014
Available online 27 May 2014

Edited by Ulrike Kutay

Keywords:
Poly(A) polymerase (PAP)
Canonical PAP
PAP isoforms
PAPα
Star-PAP
P4.5Pα
PIPKIα
CK1
Polyadenylation
Uridylation
3′-end processing
Oxidative stress

Abstract

Almost all eukaryotic mRNAs acquire a poly(A) tail at the 3′-end by a concerted RNA processing event: cleavage and polyadenylation. The canonical PAP, PAPα, was considered the only nuclear PAP involved in general polyadenylation of mRNAs. A phosphoinositide-modulated nuclear PAP, Star-PAP, was then reported to regulate a select set of mRNAs in the cell. In addition, several non-canonical PAPs have been identified with diverse cellular functions. Further, canonical PAP itself exists in multiple isoforms thus illustrating the diversity of PAPs. In this review, we compare two nuclear PAPs, Star-PAP and PAPα with a general overview of PAP diversity in the cell. Emerging evidence suggests distinct niches of target pre-mRNAs for the two PAPs and that modulation of these PAPs regulates distinct cellular functions.

© 2014 The Author. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).

1. Introduction

In eukaryotes, nuclear mRNA synthesis is a multistep process that begins with transcription and ends with processing at the 3′-UTR [1–5]. The various steps of mRNA synthesis – transcription, splicing, and 3′-end formation are functionally interconnected through a network of synergistic interactions [3,6]. The 3′-end processing of a precursor mRNA (pre-mRNA) is an essential step in eukaryotic gene expression, which is comprised of two steps – cleavage and addition of poly(A) tail [1,4,5,7,8]. Almost all eukaryotic mRNAs are polyadenylated, a step critical for stability, export and translation efficiency of mRNAs [1,4,5,7,9]. Pre-mRNAs are polyadenylated by enzymes called poly(A) polymerases (PAPs) which function in a 3′-end processing complex comprised of a large number of protein constituents [11].

The canonical PAP exists in multiple isoforms and at least three forms of canonical PAP – PAPα, PAPβ (PAPT), and PAPγ (neoPAP) have been reported [12–18]. Canonical PAPs were considered the only PAPs that controlled all co-transcriptional polyadenylation in the nucleus. Apart from PAPα, PAPβ also functions in the similar CPSF and AAUAAA signal dependent polyadenylation of pre-mRNAs in the nucleus [13]. Another nuclear non-canonical PAP, Star-PAP [Speckle Targeted PIPKα Regulated Poly(A) Polymerase] (RBM21, TUT1), was then reported to polyadenylate certain mRNAs involved in various cellular processes such as oxidative stress response and apoptosis [19,20]. Based on similarities in domain architecture, Star-PAP belongs to a subfamily of non-canonical PAPs (ncPAPs). So far, seven known ncPAPs have been reported in humans with diverse cellular functions [21,22].

PAPs and Star-PAP participate in both cleavage and polyadenylation reactions. In addition, Star-PAP exhibits terminal uridylyl transferase activity toward U6 snRNA [23]. Do the two PAPs compete for target mRNAs? Emerging evidence suggests distinct niches of target mRNAs for each PAP and there appears to be no cross regulation of their targets [19,20,24]. Such specificities in target poly(A) site recognition could potentially modulate alternative polyadenylation (APA). This review presents an overview of diverse PAPs in the cell and compares two functionally similar but distinct
nuclear PAPs, Star-PAP and PAPx. Here, we explore the differences in properties, mechanism, target mRNA selection, and regulation of the two PAPs in 3'-end pre-mRNA processing.

2. 3'-end pre-mRNA processing in gene expression

The 3'-UTR of an mRNA is critical for the regulation of gene expression. During eukaryotic mRNA maturation, the nascent pre-mRNA undergoes processing at the 3'-UTR. This processing at the 3'-end is a two-step event: first, the pre-mRNA is endonucleolytically cleaved at the cleavage site, followed by the addition of poly(A) tail to the upstream fragment of the cleaved RNA, while the downstream fragment is rapidly degraded [1,4,5,7,8,10]. 3'-end processing is intricately coupled to transcription and splicing, and also regulates the type, and the amount of mRNA and protein levels of a particular gene. Thus, mRNA 3'-end formation links transcription of a gene with the translation of its mRNA [2,6].

Mass spectrometry analysis identified ~85 protein factors associated in the 3'-end processing complex [11]. Some of the critical proteins required for the cleavage and polyadenylation reactions include subunits of Cleavage and Polyadenylation Stimulatory Factor (CPSF), Cleavage Stimulatory Factor (CstF), Cleavage Factor Im (CF Im), and Cleavage Factor Imα; Symplekin, PAP, and the nuclear Poly(A) Binding Protein (PABPN1) [for review [5,25]]. Mammalian CPSF consists of six polypeptides – CPSF 160 (CPSF1), CPSF 100 (CPSF2), CPSF 73 (CPSF3), CPSF 30 (CPSF4), hFip1 and WDR33. CPSF 160 recognises the poly(A) signal, PAS (AAUAAA), a sequence located approximately 15–30 nucleotide upstream of cleavage site and interacts with PAP and CstF [26]. Although CPSF 160 binds to the AAUAAA signal and cooperates with other factors, the assembly of the stable cleavage complex requires an intact CPSF complex [26–28]. The CPSF interaction also requires cooperation with CstF and CF Imα for stable association with pre-mRNA [29–32]. Studies suggest that other trans-acting factors such as splicing factor U1 snRNP interacts with CPSF 160 and promotes its binding to PAS on the pre-mRNA [33]. In HIV, CPSF 160 can also interact with sequence element upstream of the poly(A) site other than the classical AAUAAA signal at the 3'-UTR [34,35]. Another subunit of CPSF, CPSF 73, acts as endonuclease, binds directly to the cleavage site in a AAUAAA dependent manner and then cleaves the pre-mRNA at the cleavage site [36,37]. CPSF 30 may cooperate with CPSF 160 in RNA binding [38]. hFip1, one additional CPSF subunit, also binds PAP and directs PAP to the cleavage site [39]. The exact functions of CPSF 100 and WDR33 subunits are yet undefined [11,40].

The CstF complex recognises the GU/U rich downstream sequence element (DSE) and cooperates with CPSF. CstF has three subunits – 50 (CSTF1), 64 (CSTF2) and 77 (CSTF3) KDa of which CSTF 64 binds the GU/U rich downstream sequence element (DSE) [30,41,42]. CstF 77 functions as a homodimer and bridges the 64 and 50 KDa subunits and cooperates with CPSF 160; CstF 50 interacts with the RNA Polymerase II (Pol II) C-terminal domain (CTD) [26,43,44]. The interaction of CstF and CPSF complexes and their corresponding associations with DSE and PAS is considered the most significant event in defining the cleavage site. CF Imα is a heterotetramer with two 25 KDa subunits (CPSF5 or NUDT21) that forms the core of the complex along with two larger polypeptides of 68 KDa (CPSF6) and/or 59 KDa (CPSF7) subunits. CPSF5 binds pre-mRNA upstream of PAS to a sequence element that contains the U(G/A)UA motif. In addition, CF Imα cooperates with CPSF for RNA binding and enhances the recognition of the cleavage site [31,45–47]. CF Imα can also direct a sequence-specific AAUAAA-independent polyadenylation by recruiting the CPSF subunit hFip1 and PAP in vitro [48]. CF Imα consists of two subunits, hPcf1 and hClp1, and possibly links CF Imα and CPSF within the cleavage complex [49]. Symplekin is a scaffolding protein that putatively joins a large number of proteins together in the complex [50–53]. CPSF, CstF, Symplekin and CF Imα interact with each other stabilising the 3'-end processing complex assembled on pre-mRNA and promotes recruitment of PAPx. Mammalian PAPx is also required for the cleavage reaction, however, the mechanism as to how PAPx is involved in cleavage is not precisely defined [5,25]. After cleavage of the transcript, PAPx adds a poly(A) tail to the upstream fragment of cleaved RNA. The nuclear poly(A) binding protein (PABPN1) binds the nascent poly(A) tail, confers processivity to PAP and controls poly(A) tail length. PABPN1 also interacts with PAP and CF Imα and enhances the efficiency of polyadenylation [54–60]. Thus, a large number of protein factors cooperate with each other and assemble at the 3'-UTR to accomplish cleavage of the transcript followed by polyadenylation.

3. Polyadenylation

Polyadenylation is a process of template-independent addition of a long poly(A) tail to the 3'-end of an mRNA. Polyadenylation activity was first identified some 50 years ago from calf thymus nuclei extracts [61]. However, it was only a decade later that poly(A) tails were recognised as a product of post-transcriptional processing of the mRNA 3'-UTR [62–64]. Almost all mammalian mRNAs have a poly(A) tail at their 3'-end, with the exception of histone mRNAs which ends after a highly conserved RNA stem-loop structure, and lacks a poly(A) tail [65]. The length of a nascent polyadenylated tail on an mRNA in mammalian cells varies from 200 to 300 adenosine residues [1,9]. In the nucleus, the poly(A) binding protein, PABPN1 helps to define the length of the newly synthesised poly(A) tail during de novo mRNA synthesis [5,54,56]. PABPN1 interacts with the first 11 polyadenosine residues added, stimulates PAP affinity for RNA substrate, and in presence of CPSF induces PAP from its distributive mode to a processive mode of polyadenylation [54,60,65]. When polyadenylation reaches ~250 residues, PAP switches back to its distributive mode resulting effectively in termination of polyadenylation [58]. The precise mechanism of this length control is not fully known, it appears to occur through the formation of a ~20 nm spherical structure involving the poly(A) tail and the bound PABPN1 disrupting the tripartite, CPSF-PAP-PABPN1 processive polyadenylating complex [56,67]. Additionally, a role of multi-functional protein nucleophosmin (NPM1) in poly(A) tail length determination has also been proposed [68,69]. However, a recent poly(A) tail profiling indicated much shorter average lengths of poly(A) tails from various eukaryotic species (<100 in mammalian cells) [70] likely due to the shortening in the cytoplasm [71]. Another genome wide measurement of poly(A) tail length also demonstrated a median tail length of 50–100 adenosine nucleotides in HeLa and NIH 3T3 cells [72]. The observed length of mammalian poly(A) tails is at least influenced or maybe determined by the shortening reaction in the cytoplasm. In addition, there was diversity in the tail length not only among the transcripts from different individual genes but also within different mRNA transcripts from the same gene. Intriguingly, shorter tails were observed for mRNAs encoding ribosomal or housekeeping proteins [70]. In general, poly(A) tails play crucial roles in maintaining mRNA stability and turnover, transport of message from nucleus to cytoplasm, and translation efficiency of mRNA [1,5,9,10]. Moreover, defective polyadenylation has been linked to various human diseases [73].

3.1. Alternative polyadenylation (APA)

In humans, pre-mRNAs are polyadenylated in several different ways due to the existence of more than one polyadenylation site, allowing a single gene to encode multiple mRNA transcripts.
4. Poly(A) polymerase (PAP)

PAPs are the enzymes involved in the polymerisation of adenosine residues to form long poly(A) tails at the 3′-end of eukaryotic mRNAs. PAPs are involved not only in the polyadenylation reaction but also in the CPSF mediated cleavage reaction [1]. The gene structure of PAP indicated possible different PAP isoforms by alternative RNA processing [93]. Consistently, different PAP isoforms have been isolated from various sources [18,94–96].

4.1. Canonical PAP (PAPα) – the nuclear enzyme

Canonical PAPα belongs to a nucleotidyl transferase superfamily of DNA Polymerase β [97,98], and is responsible for the polyadenylation of nascent mRNAs in the nucleus. PAPα has three distinct domains: a catalytic domain at the N-terminus, an RNA binding region, and two C-terminal nuclear localisation signals (NLS1 and NLS2) followed by a ~20 KDa extended region enriched in serine (S) and threonine (T) residues [99–102]. Crystal structure of mammalian PAPα showed an aspartate triad in the active site similar to the DNA pol β coordinating the metal ions required for catalysis and ATP recognition [99,101,103,104]. Interestingly, the C-terminal S/T rich region is highly phosphorylated [99,100,102,105,106]. Moreover, there are seven cyclin dependent phosphorylation sites in this region [106–108]. Phosphorylation at these sites represses the PAP activity. Phosphorylation of PAP will be discussed in a later section. In addition, interaction sites for U1A and U2AF65 splicing factors are present at the C-terminus [109–111] indicating the regulatory potential of the C-terminal end.

4.2. Multiple isoforms of canonical PAP

In humans, three genes encode the canonical PAP – PAPOLA (PAPα), PAPOLB (PAPα or T) and PAPOLG (PAPγ or neoPAP). While PAPα is ubiquitously expressed, PAPβ is testis-specific and regulates transcripts expressed during spermatogenesis [12,14,15]. Both PAPT and PAPγ share similar structural motifs and sequence identity with PAPα, except for the divergent C-termini. These different forms of PAP (PAPα, β, or γ) are believed to have arisen from a common PAP by gene duplication [12,13,15]. PAPγ appears to have the same function in cleavage and polyadenylation as that of PAPα. Interestingly, PAPγ exhibits monoadenylation activity towards small RNAs in addition to its normal PAP activity [112]. Furthermore, PAPγ was found to be specifically active during tumourigenesis, thus suggesting functional diversity [13,17]. Apart from these different forms of PAP, there exists other PAP related genes in humans. At least two such PAP related gene sequences have been identified from the in silico searches in the human genome [113].

There are at least six isoforms of canonical PAPα generated by alternative splicing, PAP I–VI [16,18,96]. PAPs I, II and IV are longer versions with the full length catalytic domain while III, V and VI are truncated PAPs lacking parts of the catalytic domain. PAPs I, II and IV are functionally active, and are generated by alternative splicing of the last three exons [16,18]. PAP II is the predominant PAP isoform in most cell types [16,94,114]. Truncated PAPs, PAPs III, V and VI lack NLSs, the extended C-terminus in addition to parts of the catalytic domain. These PAPs are generated by alternative polyadenylation and/or splicing events, and do not encode functional proteins in vivo [18,100,115]. Two additional longer PAP isoforms (PAP VIII and IX) generated by alternative splicing of exons 20, 21 and 22 have also been reported [116]. However, at this time the significance of divergent C-termini of the full length PAPs is unclear. Interestingly, the C-terminal S/T rich region which is present in all longer PAP isoforms is dispensable for its activity in vitro [16,102]. Therefore, it is likely to act as a regulatory domain, and it could have a selective advantage of differential interaction with other distinct trans-acting cleavage factors or regulators resulting in functional diversity. Moreover, studies have shown distinct cellular functions for different PAP isoforms in plants [117]. Schematics of various human PAP isoforms have been depicted in Fig. 1.

4.3. Non-canonical PAP (ncPAP) – PAPs with functional diversity

ncPAPs are PAP-related members of the Pol β superfamily involved in diverse cellular functions as detailed below. Unlike the canonical counterparts, which add long poly(A) tail during mRNA maturation, ncPAPs typically add short terminal tails and target a variety of substrates (snRNA, miRNA, aberrant rRNA, snoRNA, histone mRNA, etc.). Surprisingly, there are reports of polyadenylation of select pre-mRNAs by one of the ncPAP, Star-PAP (discussed in detail in the following sections) [19,20]. This is an unusual function for an ncPAP as most ncPAPs add short tails. In addition, ncPAPs have distinct domain architecture. For example, all ncPAPs contain a conserved (among ncPAPs) PAP associated domain immediately following the catalytic (PAP) domain (Fig. 1). There are at least seven potential ncPAPs in humans (PAPD1, PAPD4, PAPD5, Pols, RBM21, ZCCHC6, ZCCHC11). PAPD1 (hmtPAP) is a mitochondrial PAP that polyadenylates mitochondrial mRNA [118]. PAPD1 mediated polyadenylation can generate UAA stop codon in some mitochondrial mRNAs, which is not encoded by the mitochondrial DNA [119–121]. However, the functional significance of mitochondrial polyadenylation is still a topic of debate [118,121,122]. PAPD1 was also reported to uridylate histone mRNA along with PAPD5 to target it for degradation [123] although the actual PAP that uridylates histone mRNA is somewhat controversial [124]. hGLD2 (PAPD4) is a cytoplasmic PAP that polyadenylates short (A)-tailed mRNAs in the cytoplasm [125,126] and is involved in diverse functions such as embryonic development, cell cycle, germline maturation, synaptic plasticity, learning and memory [126–131]. hGLD2 also polyadenylates p53 mRNA in the cytoplasm [128,132]. hGLD2 targets mRNAs containing a cytoplasmic polyadenylation element (CPE) at the 3′-UTR that is recognised by the regulatory protein CPEB (CPE binding protein). Phosphorylated CPEB interacts with CPSF 160 and helps recruit the CPSF complex (CPSF 160, 100 and 30) to the PAS. This complex is then stabilised by another processing factor, symplekin. This processing complex then recruits the cytoplasmic PAP, hGLD2 at the 3′-end to elongate the poly(A) tail [129,133,134]. Unlike the nuclear polyadenylation complex, the CPSF 73 subunit is not present in the cytoplasmic polyadenylation complex [135].
by the exonuclease PARN to generate mature 3'-ends [141]. Another ncPAP, Star-PAP (RBM21), controls 3'0-end processing of mRNAs involved in oxidative stress response[20]. Star-PAP also shows uridylation activity toward U6 snRNA substrate [23] (discussed in detail in subsequent sections). ZCCHC11 (TUT4) and ZCCHC6 (TUT7) are orthologues of yeast Cid1 uridyl transferase with extensive homology to each other and regulate diverse RNA species [21,124,142–145]. ZCCHC11 and ZCCHC6 uridylate miRNA let-7 precursor through interaction with Lin 28, thus controlling let-7 biogenesis [144,146–148]. Further, ZCCHC11 mediated uridylation controls microRNA, miR-26 activity [145]. and has also been implicated in histone mRNA degradation [124]. Thus, the existence of various canonical and non-canonical PAPs suggests diverse functional significance of PAPs in the cell. A list of various human canonical and non-canonical PAPs can be found in Table 1.

4.4. Star-PAP – a schizophreinic polymerase

Star-PAP (Speckle Targeted PIPKIz Regulated Poly(A) Polymerase) is a nuclear ncPAP regulated by lipid messenger phosphatidylinositol 4,5 bisphosphate (PI(4,5)P2) [20,149–151]. Star-PAP was identified as an interacting partner of phosphatidylinositol phosphate kinase Ix (PIPKIz) [20]. Star-PAP contains a PAP domain split by a proline rich region (PRR) of ~200 amino acids that is phosphorylated by casein kinase I (CKI) isoforms α and ε [152,153]. Star-PAP has two polynucleotide binding domains – a zinc finger (ZF) and an RNA recognition motif (RRM), both required for Star-PAP RNA binding [24]. Star-PAP and PAPβ have similar function but with a distinct mechanism regulating a select set of mRNAs [20,24]. Star-PAP along with PIPKIz specifically control genes involved in the oxidative stress response such as heme oxidase-1 (HO-1) and NAD(P)H:Quinone Oxidoreductase (NQO-1) [20,152] and the pro-apoptotic gene Bcl-2 interacting killer (BIK) [19].

Star-PAP was initially identified as U6 terminal uridylyl transferase (TUTase), which uridylates U6 snRNA [23] involved in cellular splicing [23,154]. Concomitantly, siRNA knockdown of Star-PAP was reported to dramatically reduce cell viability. However, the exact reason for loss in cell viability is unclear. Given Star-PAP’s apparent role in 3’-terminal modification of U6 snRNA, it is tempting to think of a global impact of Star-PAP on splicing efficiency. However, at present, there is no direct evidence to suggest any role for Star-PAP or a U6-TUTase-catalysed reaction in cellular splicing [23,155,156]. Alternatively, Star-PAP as a PAP is involved in various cellular processes including stress response and apoptosis. Microarray data indicated that a number of Star-PAP targets are genes critical for cell survival [19,20]; thus, loss of Star-PAP could result in cell death. Surprisingly, the study that identified Star-PAP as a

---

Fig. 1. Schematic representation of the domain architecture of human PAPs. Canonicals – PAPα, three functional splice isoforms, PAPβ (PAPT), PAPγ (neoPAP); and non-canonicals – Star-PAP, hGLD2 (PAPD4), hmtPAP (PAPD1), ZCCHC11 are shown. All canonical PAPs including the splice isoforms have similar structural organisation (except divergence at the C-terminus), comprising a catalytic domain (PAP domain) – red, an RNA binding domain – blue, nuclear localisation signals – green, and a C-terminal Ser/Thr rich regulatory region – brown. Non-canonical PAPs have diverse organisation comprised of a catalytic domain (PAP or PUP) – red, a PAP associated domain – yellow, RNA recognition motifs (such as ZF – orange, Lucine Zipper – magenta, an RNA binding domain – blue, RNA recognition motif – light blue), and Nuclear localisation signals – green. In addition, Star-PAP PAP domain is split by a proline rich region (pink). The size of each protein is indicated (not to scale).
PAP did not report any significant effect of siRNA Star-PAP knockdown on the cell viability [20]. In addition, the yeast counterpart Cid11 is not required for cell viability [22]. Nevertheless, Star-PAP uridylation activity has been confirmed in vitro [20,23].

Is Star-PAP a PAP or a TUTase or both in vivo? Although Star-PAP has both PAP and TUTase activities, at the physiological concentration of ATP adenylation activity competes over uridylation suggesting a possible predominance of polyadenylation function in the cell [20]. Nonetheless, with a clear in vitro TUTase activity of Star-PAP, one can envisage a distinct physiological role of Star-PAP uridylation function in the cell. In fact, many ncPAPs have both uridylation and adenylation functions [118,120–123,140]. Therefore, it is conceivable that Star-PAP has a complex role, for example, while polyadenylation regulates a select set of mRNAs, uridylation regulates U6 or other target RNAs. Another possibility is that both activities combined result in a heterogeneous 3′-end tail with both A′s and U′s. A related example has been reported in fission yeast where few Us were incorporated at the end of the 3′-poly(A) tail [157,158]. This modification has been implicated in a new pathway of 5′-3′ mRNA degradation in fission yeast, where addition of short terminal Us at the end of polyadenylated mRNAs appears to stimulate decapping and initiates the mRNA degradation pathway [158]. Widespread uridylation has also been reported downstream of the mammalian mRNA poly(A) tail [72]. Furthermore, Dis3L2, a new 3′-5′ exonuclease, involved degradation of oligouridylated RNAs, was recently identified in multiple eukaryotes [159–161]. Dis3L2 functions independent of the exosome, and uridylation of its targets acts as an RNA decay signal for Dis3L2. Moreover, addition of >10 uridines to the 3′-end of its miRNA target stimulates Dis3L2’s enzymatic activity in vitro [159–161]. These studies also suggest a possible general role of terminal uridylation as signal for RNA decay in eukaryotes. Thus, presence of Us in the poly(A) tail will have a profound impact on the functional dynamics of an mRNA. Unfortunately, no sequence information of Star-PAP target poly(A) tails is available so far, and hence worthwhile exploring. Such properties, as mentioned above, would make Star-PAP schizophrenic in nature, or a truly non-canonical enzyme.

5. Mechanism of 3′-end RNA processing – Star-PAP versus canonical PAP

Cis-elements present at the 3′-UTR play an important role in specific cleavage and polyadenylation of pre-mRNAs. There are at least four consensus cis-elements at the canonical 3′-UTR [7]. The first important motif is a conserved hexamer AAUAAA (PAS), which determines the position of the cleavage site. Mutation in this consen sus hexamer affects the efficiency of 3′-end processing [162,163]. Point mutations in the AAUAAA signal have often been linked to human diseases. For example, two point mutations in the AAUAAA hexamer have been characterised in patients suffering from thalassaemia (AAUAGG in the β-globin and AACHAA in the β-globin) [164,165]. An A→G point mutation (AAUAAA – AAGUAA) in FOXP3 gene results in a rare X-linked autoimmune disorder, IPEX (immunodysregulation polyendocrinopathy enteropathy X-linked syndrome) [166]. However, variation in the second nucleotide in the consensus hexamer to U (AUUAAA) is the most widely occurring PAS after AAUAAA (for reviews [1,167]). Studies on human and mouse ESTs have indicated AAUAAA (70%) as the most common hexamer followed by AUUAAA (15–20%) among all PAS containing ESTs [76,168]. Analysis of human UTRs and ESTs has indicated alternate signals as well. AGUAAA, UAUAAA, CAUAAA, GAUAAA, AUUAA, AAUACA, ACUAAA and ACUAAA are few other widely occurring hexamers [168,169]. However, such variants (including the common AUUAAA hexamer) are less efficiently processed than the classical AAUAAA [168]. The second important cis-element at the 3′-UTR is the cleavage site situated 20–40 bases downstream of PAS. This position of the cleavage site is determined by the locations of both PAS and DSE [30,170]. Although the sequence at the cleavage site is not very conserved, in vertebrates the majority of the cleavage sites are located immediately downstream of an adenosine residue (with preference for A over G), the most optimal site being CA [25,163]. In fact, in the human prothrombin gene, the position of the cleavage site is determined by the locations of both PAS and DSE [30,170].

Table 1
List of various human canonical and non-canonical PAPs.

| Name of the PAP | Localisation | Functional significance | Reference |
|-----------------|--------------|------------------------|-----------|
| **Canonical PAP** |              |                        |           |
| PAP-I           | Nuclear      |                        | [16,18,94,102,114] |
| PAP-II          |              |                         |           |
| PAP-III         |              |                         |           |
| PAP-IV          |              |                         |           |
| PAP-V           |              |                         |           |
| PAP-VI          |              |                         |           |
| PAP-β (PAPT)    | Nuclear/Cytoplasmic | Testes specific – spermatogenesis | [12,15] |
| PAP-γ/neopAP    | Nuclear      |                        | [13,17,112] |
| **Non-canonical PAP** |          |                        |           |
| PAPD1 (hmtPAP)  | Mitochondrial | Mitochondrial mRNA stabilisation, histone mRNA degradation, stop codon regeneration | [118,120–123] |
| PAPD4 (hGld2)   | Nuclear/Cytoplasmic | Cytoplasmic mRNA polyadenylation, mRNA stabilisation | [122,125,126,128] |
| PAPD5           | Nuclear      | Aberrant RNA degradation, histone degradation, processing of snoRNAs, various other RNA targets | [21,140] |
| POLS (PAPD7)    | Nuclear      | Not clearly defined, likely redundant to PAPD5 | [21,140] |
| ZCCHC5 (TUT 4)  | Nuclear      | Similar to ZCCHC11; regulate Let 7 biogenesis | [147,157] |
| ZCCHC11 (TUT 6) | Nuclear      |                         |           |
| Star-PAP (RBM 21, TUT1) | Nuclear | mRNA regulation (let7, mi256 and others), histone mRNA degradation | [124,143,147,157] |

For review [127,129] For review [21,139–141] For review [127,129] For review [127,129]
downstream of the cleavage site, which also influences the position of the cleavage site. It is less conserved than the PAS and has either a GU-rich (YGGGUYY, where Y = pyrimidine) or a U-rich (UUUUU) element [174–177]. And, finally the last cis-element is a U-rich, upstream sequence element (USE) situated ~1–20 nucleotides upstream of PAS [7]. USEs can influence the efficiency of PAS and/or complement for the suboptimal PAS or DSE [35,178–181]. In addition, there are auxiliary upstream and downstream sequence elements. While the auxiliary upstream sequence mostly contains either U rich (UUUU) or UAUA/UGUA, the auxiliary downstream sequences are generally G-rich [182–185] (for review [5,25]). They are less conserved in position as well as sequence than the four core elements.

Except for the intact AAUAAA signal, Star-PAP target messages harbour other cis-elements at the 3′-UTR that are distinct from that of canonical 3′-UTR [19]. Star-PAP targets have suboptimal DSEs, with U/GU deplete sequence, which potentially renders CstF dispensable for Star-PAP mediated 3′-end processing. In addition, there is no noticeable canonical motif like USE; instead, a ~40–60 nucleotides long GC-rich sequence of Star-PAP binding region upstream of the PAS is present [19,24]. These variations in the cis-regulatory elements of Star-PAP and canonical PAS target 3′-UTRs explain the mechanistic differences of the two PAPs. A comparison of the 3′-UTR cis-elements of canonical and Star-PAP regulated genes is depicted in Fig. 2.

Recent advances in the understanding of 3′-end processing have indicated distinct mechanisms for different PAPs. While PAPx is mechanistically well explored, studies on Star-PAP are still emerging. The two PAPs share similar cleavage factors but assemble distinct 3′-processing complexes and control specific sets of target mRNAs in the cell. Around 85 proteins are associated with the canonical 3′-end processing complex. Emerging evidence suggests that Star-PAP may not require all canonical cleavage factors, while requiring additional proteins not present in the canonical 3′-end processing machinery. In the canonical mechanism, CPSF 160 binds the PAS, cooperates with CstF and Cleavage factor I (CF I). CPSF 160 then recruits PAPx through direct interaction at the cleavage site [26,28,29,45]. PAPx has low affinity for RNA substrate and lacks RNA binding specificity [100,114]; and no precise role of PAPx in the cleavage reaction has been defined. In contrast, Star-PAP directly binds pre-mRNA and plays a structural role to assemble the cleavage complex. Star-PAP directly interacts with CPSF 160 and 73 [19,24]. Star-PAP binding to the pre-mRNA and CPSF 160 recruits CPSF 160 to the PAS. CPSF 73 is then recruited to the cleavage site by its interaction with CPSF 160 and Star-PAP [24]. The mechanism of canonical PAS and Star-PAP mediated 3′-end processing is shown in Fig. 3.

Star-PAP has two RNA binding motifs: a Zinc Finger (ZF) and an RNA recognition motif (RRM), both required for mRNA binding [24]. This implies a complex binding motif of Star-PAP on its target RNA with multiple nucleotide elements that in combination interact with ZF, RRM, or both. This is consistent with the large Star-PAP footprint observed on targets, HO-1 and BIK UTR RNA [19,24]. The multiple binding elements could in turn enhance both specificity and flexibility for targeting specific pre-mRNAs. Moreover, Star-PAP and CPSF submits 160 and 73 reconstitute cleavage of HO-1 UTR RNA in vitro. The resulting 3′-cleavage is specific but weak, suggesting that optimum in vivo cleavage requires other processing factors [24]. In contrast, no combinations of recombinant cleavage factors from the canonical mechanism could reconstitute in vitro cleavage reaction. This demonstrates that Star-PAP mediated 3′-end processing requires different sets of cleavage factors. In addition, due to low U/GU DSE on Star-PAP target mRNAs CstF which otherwise cooperates with CPSF-RNA binding in the canonical mechanism is likely dispensable in the Star-PAP mediated 3′-end processing mechanism [19]. Alternatively, different combinations of cleavage factors might function with specific PAPs (Star-PAP and PAPx) to regulate distinct target messages.

6. Implications of PAP diversity – Star-PAP vs canonical PAP

While the diversity of cellular PAPs is well known, the significance of PAP multiplicity is not clear. Multiple lines of evidence suggest the involvement of different PAPs in distinct cellular functions as illustrated by the functional specificities of various canonical isoforms and non-canonical PAPs. For example, ncPAPs such as hGLD2 or PAPD1 have specific roles in regulating cytoplasmic or mitochondrial mRNAs [118,121,126,135] while canonical PAPs such as PAPβi and PAPγ specifically regulate mRNAs during spermatogenesis and tumourigenesis respectively [12,15,17]. Moreover, longer canonical PAPs isoforms, I and IV exhibit tissue dependent expression [18]. On the other hand, Star-PAP regulates specific mRNA targets in the nucleus, which are otherwise inaccessible to PAPx [20,24]. Therefore, the regulation of distinct PAPs might differentially control expression of specific mRNAs.

6.1. Multiple types of 3′-end tail formation

There are two basic types of 3′-end tails reported so far: poly(A) tail and short terminal (U)-tail, both of which can have either destabilising or stabilising functions on RNA target. For example, poly(A) tails on mRNAs primarily confer stability to the transcript, while polyadenylation of aberrant tRNAs targets them for degradation [139,140]. Such destabilising function of poly(A) tail is well established in prokaryotic polyadenylation [186,187]. In general, polyadenosine tail present on mRNA 3′-ends can be either long poly(A) tail with stabilising function as in regular mRNA formation, or shorter (A) tail that destabilises RNA for degradation [9].

![Fig. 2. 3′-UTR consensus cis-elements of canonical and Star-PAP target 3′-UTRs. The canonical 3′-UTR has distinct consensus elements such as the AAUAAA poly(A) signal, cleavage site ~15–30 nucleotide downstream of PAS, G/GU rich DSE and a U-rich USE (for a review see Ref. [7]). In case of Star-PAP target mRNAs, except for the intact PAS (AAUAAA), they have suboptimal DSEs (deplete U sequence), and no regular USE present; instead, a GC-rich Star-PAP binding region is found around 40–50 nucleotides upstream of the cleavage site is present.](image-url)
Further, small RNAs such as miRNAs as well as histone mRNAs are 3′-uridylated, apparently destabilising the RNA [123,124,188,189]. In contrast, oligo (U)-tailing of human U6 snRNA has a stabilising function [23,188]. In yeast, an additional type of 3′-end tail has been reported where the poly(A) tail is followed by a short U tract that results in degradation of the mRNA [158]. PAPα forms poly(A) tail at the 3′-end, and Star-PAP makes both poly(A) tails (like canonical PAPα) and also short terminal U tails (like a non-canonical PAP) to distinct target RNAs. Given the enzymatic character of Star-PAP and the number of target mRNAs it controls [20,23], there could be yet another type of a heterogeneous 3′-end tail having both As and Us in the cell. Such tails would have entirely different properties from that of either poly(A) or U tails [157,190].

6.2. Specificity for target mRNAs

It is clear that the two nuclear PAPs PAPα and Star-PAP control distinct mRNA targets in the nucleus. However, it is unclear why Star-PAP target mRNAs are specific to Star-PAP and not accessible to PAPα, and vice versa. A possibility for the specificity is the Star-PAP binding to its target pre-mRNA. Star-PAP footprint on its targets HO-1 and BIK pre-mRNA indicated a GC-rich sequence /C24–60 nucleotides upstream of the cleavage site [19,24] which is present on all Star-PAP target mRNAs [19]. RNA-compete analysis has also identified a specific Star-PAP (TUT1) binding oligonucleotide (-AUA-) motif [191]. This motif is present within the GC-rich sequence of Star-PAP footprints of all target mRNAs so far studied [19,24], suggesting that this motif might provide selectivity to Star-PAP for its target messages. However, this fails to explain why PAPα cannot process Star-PAP target messages even though intact canonical AAUAAA signal and cleavage site are present. Sequence analysis has shown a U/GU deplete DSE in Star-PAP target pre-mRNAs, which is critical for CstF binding [19]. Therefore, another possible explanation for PAPα exclusion from the Star-PAP regulated transcripts could be the low U/GU sequence (suboptimal DSE), which renders the pre-mRNA inaccessible to CstF, thus preventing the recruitment of PAPα. However, some of the Star-PAP target pre-mRNAs still possess DSE albeit weaker than the canonical counterparts [24]. Therefore, yet another explanation is the involvement of trans-acting factors that bind the pre-mRNA along with Star-PAP and confer specificity to Star-PAP targets. Like Star-PAP, other PAPs are also likely to have distinct sequence elements at the 3′-UTRs that determine the specificity of each PAP.

6.3. Signalling mediated regulation of polyadenylation

Star-PAP is regulated by signalling pathways through distinct kinases. Like Star-PAP, PAPα too is regulated by phosphorylation; however, the extracellular signal that triggers PAPα phosphorylation is unclear. Several serine and threonine residues within the extended C-terminus of PAPα are phosphorylated by cdc2-cyclin B [105,106]. During the mitotic phase of the cell cycle, this region is hyperphosphorylated to inhibit PAP activity, which is then reversed in the G1 phase [106]. Thus, this exemplifies a conditional or temporal regulation of PAP by phosphorylation as per cellular requirements. In addition, reports suggest that phosphorylation of PAPα by ERK kinase promotes the PAP activity [192]. PAP phosphorylation could also modulate the interaction with other cleavage factors to regulate distinct cellular functions. Thus, regulation of PAP could be an important mechanism for the cellular control of gene expression.

On the other hand, Star-PAP activity and its target gene expressions are stimulated by oxidative stress and nuclear PI4,5P2 [20,24]. The kinases and upstream signalling events modulating
Star-PAP upon stress induction or DNA damage are well defined. Star-PAP associates with Ser/Thr kinase casein kinase I (CKI) \cite{193,194}, and protein kinase C\(\text{d}\) (PKC\(\text{d}\)) \cite{195–197}. Star-PAP is phosphorylated at the proline rich region (PRR) in the catalytic domain by CKI isoforms \(\alpha\) and \(\varepsilon\), which is critical for Star-PAP activity \cite{152,153}. Knockdown of casein kinase or dephosphorylation of Star-PAP resulted in diminished Star-PAP activity. The PRR contains several putative CKI phosphorylation sites, and is likely to be phosphorylated at multiple sites. Both CKI isoforms together regulate 3′-processing of Star-PAP target HO-1 mRNA \cite{153}. Oxidative stress treatment resulted in the induction of Star-PAP phosphorylation indicating the involvement of a stress signalling pathway coupled with phosphorylation to regulate Star-PAP.

Unlike the CKI isoforms, PKC\(\text{d}\) regulates Star-PAP activity downstream of DNA damage signalling \cite{19}. PKC\(\text{d}\) interacts with and phosphorylates Star-PAP. Interestingly, PKC\(\text{d}\) is required for the DNA damage signal induced Star-PAP activity, but not for the oxidative stress induced pathway. While CKI and the stress induced pathway regulate genes involved in oxidative stress response such as HO-1 and NQO-1, DNA damage and PKC\(\text{d}\) regulate the pro-apoptotic gene BIK. This signifies a signal mediated differential regulation of Star-PAP target genes. Thus, modulation of PAP by different signalling pathways regulates genes involved in distinct cellular functions suggesting that PAPs act as regulatory molecules that alter gene expression to mediate selective or conditional gene expression. Differential regulation of Star-PAP by distinct signalling pathways is depicted in Fig. 4.

6.4. Alternative polyadenylation

The requirements of distinct cis-elements at the 3′-UTR of Star-PAP target genes have been discussed above. All nuclear pre-mRNA UTRs can have either Star-PAP specific or canonical PAP specific cis-element (poly(A) site). Reports indicate that more than 50% of mRNAs have multiple poly(A) sites at their 3′-UTRs \cite{76}. It is likely that at least few of such mRNAs contain both Star-PAP and PAP\(\alpha\) specific cis-elements at the 3′-UTR. This would result in alternate selection of poly(A) sites by poly(A) polymerases. The regulation of specific mRNAs or target 3′-UTRs by distinct canonical PAP isoforms has been reported in plants \cite{117}. Several Star-PAP target genes identified in the microarray analysis also harbour more than one poly(A) site \cite{20}. For example, NQO-1 has three poly(A) sites of which mRNA encoded by the most distal site is induced by the toxin dioxin.\cite{198}. Knockdown of Star-PAP resulted in the loss of NQO-1 expression \cite{20} suggesting that Star-PAP controls one or more poly(A) sites of NQO-1. In addition, expressions of some Star-PAP target genes are only partially diminished upon Star-PAP knockdown \cite{20}. Such genes could represent a set of APA regulated genes where loss of Star-PAP regulated mRNA isoform is compensated by the expression of alternate isoforms from PAP\(\alpha\) controlled poly(A) site(s) – a novel mechanism of APA site selection by PAPs.

![Fig. 4. Model for signal mediated regulation of Star-PAP to differentially control the 3′-end processing of distinct target messages. Various signal transduction components integrate into the Star-PAP 3′-end processing complex downstream of the signalling pathway, to regulate different target genes. In this model, casein kinase (isoforms \(\alpha\) and \(\varepsilon\)) works downstream of oxidative stress to specifically regulate stress response genes HO-1 and NQO-1 through Star-PAP. On the other hand, PKC\(\text{d}\) works in concert with DNA damage signal to regulate pro-apoptotic gene BIK through Star-PAP. The PKC\(\text{d}\) mediated pathway is independent of oxidative stress regulation and vice versa. Thus, Star-PAP acts as a central regulatory molecule at the 3′-end of a gene that differentially controls the expression of target genes through various kinases and signalling molecules.](image-url)
7. PAP switch/PAP selection enigma at the 3′-end

It is evident that Star-PAP and PAP\textsubscript{\textalpha} assemble distinct 3′-end processing complexes. PAP\textsubscript{\textalpha} is not detected in the Star-PAP 3′-end processing complex and vice versa [20,24]. Intriguingly, there has been growing evidence that 3′-end processing factors are closely linked to the promoter, and at least in some cases may ride with RNA Pol II complex to 3′-end [199–204] (for review [205]). Evidence suggests that 3′-processing factor(s) such as CPSF are delivered to the promoter by transcription factor TFIIID and then transferred to the elongating RNA Pol II CTD [200,201]. Other studies also suggest the recruitment of 3′-end processing factors such as CPSF and CstF at the 5′-end [206]. Consistently, in yeast cleavage factors CFI and PFI have been detected with RNA Pol II starting at the promoter [201]. Since 3′-end processing factors exist in a tight complex, it is likely that they may all be detected in association with RNA Pol II either at the promoter, or after RNA Pol II clears the promoter (for reviews [205,207,208]). Since PAPs directly interact with CPSF [24,26], it is possible that PAPs associate with RNAP-CPSF complex during transcription. However, at this point there is no direct evidence that shows PAP association with RNA Pol II. Nevertheless, ChIP experiments have shown that yeast PAP1 is localised at the promoter, though it is preferentially bound at the 3′-UTR [209]. Thus, PAPs could join RNA Pol II via CPSF interaction during transcription elongation/initiation, or be recruited specifically to the 3′-end.

Both scenarios raise an important question: what determines the choice between the two PAPs (Star-PAP and canonical PAP\textsubscript{\textalpha}) to function at a particular 3′-UTR? There are two possible models for the PAP specificity at the 3′-UTR: PAP selection, or 3′-PAP switch. In the PAP selection model specific cis-elements on the 3′-UTR RNA select the required PAP. Alternatively, in the PAP switch model the canonical PAP\textsubscript{\textalpha} predominantly associates with 3′-RNA processing-transcription complex at the 3′-UTR of all pre-mRNAs. However, a PAP switch occurs at the 3′-UTR of Star-PAP target mRNAs, to Star-PAP due to its specific binding to mRNA to assemble a stable 3′-processing complex. This model is shown in Fig. 5. This mechanism of PAP selection/switch can be extrapolated to other PAP isoforms as well. However, at present what factors drive the PAP selection/switch remains to be determined.

8. Conclusion

In recent years, much progress has been made towards the understanding of 3′-end processing mechanisms mediated by the two nuclear PAPs. Nevertheless, some key questions remain unaddressed, including the physiological significance for such variations in polyadenylation mechanisms. Indeed, the Star-PAP mediated 3′-processing complex could offer an advantage of selective regulation while employing canonical 3′-processing factors [24]. Star-PAP target genes such as HO-1 and NQO-1 are inducible stress response genes stimulated during oxidative stress [210–212]. The particular mechanism of Star-PAP dependent cleavage and its selective stimulation by oxidative stress will help home in and induce stress response genes while excluding global processing events that should remain unaffected during oxidative stress. Thus, temporal and/or specific stimulation of genes can occur through modulation of distinct PAPs, under different signalling conditions.

Current data demonstrate that diverse PAP populations function in the cell. Is the multiplicity of PAPs a cellular necessity or another functional redundancy in the cell? The answer is unknown but growing evidence suggests that the modulation of different PAPs regulate distinct cellular functions. For example, Star-PAP and PAP\textsubscript{\textalpha} are modulated by different kinases and signalling pathways to control expression of distinct target messages. Not only different PAPs but also distinct isoforms of canonical PAP\textsubscript{\textalpha} are differentially expressed, and are likely to regulate genes conditionally, or in a tissue dependent manner [12,17,18]. In conclusion, the existence of differentially regulated diverse PAP populations immensely benefits the cellular machinery for gene regulation. Although research

\[\text{Fig. 5. 3′-PAP switch/PAP selection model. In this model, a PAP switch/selection at the 3′-end of a gene favouring a particular PAP is determined by the cis-elements present on the target UTR RNA.}\]
over the last decade has considerably improved our knowledge on PAP functions, further studies are required to unravel how distinct PAPs attain specificity for their target transcripts and/or 3′UTR selection.

Acknowledgements

We thank Fiona Ukken, C. Dustin Rubinstein (University of Wisconsin-Madison) and RSL Lab members for carefully reading the manuscript. We acknowledge the funding from Wellcome Trust-Wisconsin-Madison) and RSL Lab members for carefully reading the manuscript.

References

[1] Colgan, D.F. and Manley, J.L. (1997) Mechanism and regulation of mRNA polyadenylation. Genes Dev. 11, 2755–2766.
[2] Moore, M.J. and Proudfoot, N.J. (2009) Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 136, 688–700.
[3] Proudfoot, N.J. (2004) New perspectives on connecting messenger RNA 3′ end processing to transcription. Curr. Opin. Cell Biol. 16, 272–278.
[4] Proudfoot, N. and O’Sullivan, J. (2002) Polyadenylation: a tail of two complexes. Curr. Biol. 12, R855–R857.
[5] Zhao, L., Hyman, L. and Moore, C. (1999) Formation of mRNA 3′ ends in eukaryotes: mechanism, regulation, and interrelationships with other steps in mRNA synthesis. Microbiol. Mol. Biol. Rev. 63, 405–445.
[6] Manatis, T. and Reed, R. (2002) An extensive network of coupling among gene expression machines. Nature 416, 499–506.
[7] Proudfoot, N.J. (2011) Ending the message: poly(A) signals then and now. Genes Dev. 25, 1770–1782.
[8] Wahle, E. and Ruegsegger, U. (1999) 3′ End processing of pre-mRNA in eukaryotes. FEMS Microbiol. Rev. 23, 277–295.
[9] Eckmann, C.R., Rammelt, C. and Wahle, E. (2011) Control of poly(A) tail length. Wiley Interdiscip. Rev. RNA 2, 348–361.
[10] Edmonds, M. (2002) A history of poly A sequences: from formation to factors in function. Prog. Nucleic Acid Res. Mol. Biol. 71, 285–389.
[11] Shi, Y., Di Giammartino, D.C., Taylor, D., Sarkeshik, A., Rice, W.J., Yates 3rd, T. (2002) A history of poly A sequences: from formation to factors in function. Prog. Nucleic Acid Res. Mol. Biol. 71, 285–389.
[12] Kashiwabara, S., Zhuang, T., Yamagata, K., Noguchi, J., Fukamizu, A. and Baba, T. (2000) Identification of a novel isoform of poly(A) polymerase, TPAP, specifically present in the cytoplasm of spermatogenic cells. Dev. Biol. 228, 106–115.
[13] Kyriakopoulou, C.B., Nordvarg, H. and Virtanen, A. (2001) A novel nuclear human poly(A) polymerase (PAP). PAP gamma. J. Biol. Chem. 276, 33504–33511.
[14] Lee, Y.J., Kim, H., Chung, J.H. and Lee, Y. (2001) Testis-specific expression of an intronless gene encoding a human poly(A) polymerase. Mol. Cells 11, 379–385.
[15] Lee, Y.J., Lee, Y. and Chung, J.H. (2000) An intronless gene encoding a poly(A) polymerase is specifically expressed in testis. FEBS Lett. 487, 287–292.
[16] Topalian, S.L., Bollum, F.J. and Manley, J.L. (1991) Primary structure and expression of bovine poly(A) polymerase. Nature 353, 229–234.
[17] Topalian, S.L., Kaneko, S., Gonzales, M.I., Bond, G.L., Ward, Y. and Manley, J.L. (2001) Identification and functional characterization of neo-poly(A) polymerase, an RNA processing enzyme overexpressed in human tumors. Mol. Cell. Biol. 21, 5614–5623.
[18] Zhao, W. and Manley, J.L. (1996) Complex alternative RNA processing generates an unexpected diversity of poly(A) polymerase isoforms. Mol. Cell. Biol. 16, 2378–2386.
[19] Li, W., Li, R., Li, S., St. J., Z. and Babro, C.A., Tian, B. and Anderson, R.A. (2012) Star-PAP control of BIK expression and apoptosis is regulated by nuclear MPPKalpha and PRKCdelta signaling. Mol. Cell. 45, 25–37.
[20] McCracken, S., Fong, N., Yankulov, K., Ballantyne, S., Pan, G., Greenblatt, J., Jenny, A., Hauri, H.P. and Keller, W. (1994) Characterization of cleavage and polyadenylation factor CPF specifically interacts with the pre-mRNA 3′ processing endonuclease. Nature 444, 553–556.
[21] Takagi, Y., Manley, J.L. (1994) A polyadenylation factor subunit is the human homologue of the Drosophila suppressor of forked protein. Nature 372, 471–474.
[22] Brown, K.M. and Gilmartin, G.M. (2003) A mechanism for the regulation of pre-mRNA 3′ processing by human cleavage factor Im. Mol. Cell. 12, 1467–1476.
[23] Yang, Q., Gilmartin, G.M. and Doubling, S. (2011) Crystal structure of a human cleavage factor CFI(m)25/CFI(m)68/RNA complex provides an insight into poly(A) site recognition and RNA looping. Structure 19, 368–377.
[24] Yang, Q., Gilmartin, G.M. and Doubling, S. (2013) The structure of human cleavage factor I(m) hints at functions beyond UGUA-specific RNA binding: a role in alternative polyadenylation and a potential link to 5′ capping and RNA processing. RNA 19, 748–753.
[25] Venkataraman, K., Brown, K.M. and Gilmartin, G.M. (2005) Analysis of a canonical poly(A) site reveals a tripartite mechanism for vertebrate poly(A) site recognition. Genes Dev. 19, 1315–1327.
[26] de Vries, H., Ruegsegger, U., Hubner, W., Friedlein, A., Langen, H. and Keller, W. (2000) Human pre-mRNA cleavage factor Im contains homologs of yeast proteins and bridges two other cleavage factors. EMBO J. 19, 5499–5510.
[27] Beyer, K., Dandekar, T. and Keller, W. (1996) Purification and characterization of human cleavage factor Im involved in the 3′ end processing of messenger RNA precursors. J. Biol. Chem. 271, 6107–6113.
[28] Weiss, E.A., Gilmartin, G.M. and Nevin, J.R. (1991) Pol(A) site efficiency reflects the stability of complex formation involving the downstream element. EMBO J. 10, 215–219.
[29] Lutz, C.S., Murthy, K.C., Sche, N., O’Connor, J.P., Manley, J.L. and Alwine, J.C. (1996) Interaction between the U1 snRNA-A protein and the 160-kD subunit of cleavage-polyadenylation specificity factor increases polyadenylation efficiency in vitro. Genes Dev. 10, 325–337.
[30] Gilmartin, G.M., Fleming, E.S. and Oetjen, J. (1992) Activation of HIV-1 pre-mRNA 3′ processing in vitro requires both an upstream element and TAR. EMBO J. 11, 4419–4428.
[31] Gilmartin, G.M., Fleming, E.S., Oetjen, J. and Graveley, B.R. (1995) CPSF recognition of an HIV-1 mRNA 3′-processing enhancer: multiple sequence contacts involved in poly(A) site definition. Genes Dev. 9, 72–82.
[32] Ryan, K., Calvo, O. and Manley, J.L. (2004) Evidence that polyadenylation factor CPSF-73 is the mRNA 3′ processing endonuclease. RNA 10, 565–573.
[33] Mandel, C.R., Kaneko, S., Zhang, H., Gebauer, D., Vethanathan, V., Manley, J.L., et al. (2006) Polyadenylation factor CPSF-73 is the pre-mRNA 3′-processing endonuclease. Nature 444, 553–556.
[34] Barabin, S.M., Hubner, W., Jenny, A., Minvielle-Sebastia, L. and Keller, W. (1997) The 30-kD subunit of mammalian cleavage and polyadenylation specificity factor and its yeast homolog are RNA-binding zinc finger proteins. Genes Dev. 11, 1703–1717.
[35] Edmonds, M. (2002) A history of poly A sequences: from formation to factors in function. Prog. Nucleic Acid Res. Mol. Biol. 71, 285–389.
Di Giammartino, D.C., Nishida, K. and Manley, J.L. (2011) Mechanisms and consequences of alternative polyadenylation. Mol. Cell 43, 853–866.

Jenal, M., Elonk, R., Loyza-Puch, F., van Haafken, G., Kuhn, U., Menzies, F.M., et al. (2012) The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell 149, 538–553.

Ji, Z., Zhan, X. and Tian, B. (2009) Regulation of 3' untranslated regions of mRNAs by alternative polyadenylation in generation of pluripotent stem cells from different cell types. PLoS One 4, e8419.

Kaida, D., Berg, M.C., Younis, I., Kasim, M., Singh, L.N., Wan, L., et al. (2010) U1 snRNP protects poly(A) mRNAs from premature cleavage and polyadenylation. Nature 468, 664–668.

Lou, H., Neugebauer, K.M., Gagel, R.F. and Berget, S.M. (1998) Regulation of alternative polyadenylation by U1 snRNPs and SRp20. Mol. Cell. Biol. 18, 4977–4985.

Martin, G., Gruber, A.R., Keller, W. and Zavolan, M. (2012) Genome-wide analysis of pre-mRNA 3' end processing reveals a decisive role of human cleavage factor I in selection of 3' UTR length. Cell Rep. 1, 753–763.

Morris, A.R., Bo, A., Diosdado, B., Rooijers, K., Elonk, R., Bolijn, A.S., et al. (2012) Alternative cleavage and polyadenylation during colorectal cancer development. Clin. Cancer Res. 18, 5256–5266.

Shi, Y. (2012) Alternative polyadenylation: new insights from global analyses. RNA 18, 2105–2117.

Liangouli, S., Garg, V., Yang, J.L., Leslie, C.S. and Mayr, C. (2013) Ubiquitously transcribed genes use alternative polyadenylation to achieve tissue-specific expression. Genes Dev. 27 (21), 2380–2396.

Early, P., Rogers, J., Davis, M., Calame, K., Bond, M., Wall, R., et al. (1980) Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways. Cell 20, 313–319.

Rogers, J., Early, P., Bond, M., Wall, R., et al. (1980) Two mRNAs with different 3' ends encode membrane-bound and secreted forms of immunoglobulin mu chain. Cell 20, 303–312.

Gundersen, S.I., Vagner, S., Polycarpou-Schwarz, M. and Mattaj, I.W. (1997) Involvement of the nuclear poly(A) binding protein poly(A)polymerase in U1 autoregulation and in the coupling of splicing and polyadenylation. Genes Dev. 11, 761–773.

Ballustyne, S., Bilger, A., Aström, J., Virtanen, A. and Wik sens, M. (1995) Poly(A) polymerase: biology and functions. Annu. Rev. Genet. 29, 93–140.

Rogers, J., Early, P., Bond, M., Wall, R., et al. (1980) Two mRNAs with different 3' ends encode membrane-bound and secreted forms of immunoglobulin mu chain. Cell 20, 303–312.

Gundersen, S.I., Vagner, S., Polycarpou-Schwarz, M. and Mattaj, I.W. (1997) Involvement of the nuclear poly(A) binding protein poly(A)polymerase in U1 autoregulation and in the coupling of splicing and polyadenylation. Genes Dev. 11, 761–773.

Ballustyne, S., Bilger, A., Aström, J., Virtanen, A. and Wik sens, M. (1995) Poly(A) polymerase: biology and functions. Annu. Rev. Genet. 29, 93–140.

Rogers, J., Early, P., Bond, M., Wall, R., et al. (1980) Two mRNAs with different 3' ends encode membrane-bound and secreted forms of immunoglobulin mu chain. Cell 20, 303–312.

Gundersen, S.I., Vagner, S., Polycarpou-Schwarz, M. and Mattaj, I.W. (1997) Involvement of the nuclear poly(A) binding protein poly(A)polymerase in U1 autoregulation and in the coupling of splicing and polyadenylation. Genes Dev. 11, 761–773.

Ballustyne, S., Bilger, A., Aström, J., Virtanen, A. and Wik sens, M. (1995) Poly(A) polymerase: biology and functions. Annu. Rev. Genet. 29, 93–140.
Perumal, K., Sinha, K., Henning, D. and Reddy, R. (2001) Purification, characterization, and cloning of the cDNA of human signal recognition particle RNA 3'-adenylating enzyme. J. Biol. Chem. 276, 21791–21796.

Tijer, R., Perumal, G. and Green, M.R. (2001) Expressing the human genome. Nature 409, 833–833.

Wahle, E. (1991) Purification and characterization of a mammalian polyadenylate polymerase involved in the 3' end processing of messenger RNA precursors. J. Biol. Chem. 266, 3131–3135.

Gebauer, F. and Richter, J.D. (1995) Cloning and characterization of a Xenopus poly(A) polymerase. Mol. Cell. Biol. 15, 3469.

Nordhagen, H. (2002) Functional significance of multiple poly(A) polymerases (PAPs). Acta Univ. Ups 1140, 1–51.

VI, S.L., Trost, G., Lange, P., Czecinsk, H., Rao, N., Lieber, D., et al. (2013) Target specificity among canonical nuclear poly(A) polymerases in plants modulates organ growth and pathogen response. Proc. Natl. Acad. Sci. USA 110, 13994–13999.

Tomecki, R., Dmochowska, A., Gewartowski, K., Dziembowski, A. and Stepien, P.P. (2004) Identification of a novel human nuclear-encoded mitochondrial poly(A) polymerase. Nucleic Acids Res. 32, 6001–6004.

Anderson, S., Bankier, A.T., Barrell, B.G., de Bruijn, M.H., Coulson, A.R., Drouin, J., et al. (1981) Sequence and organization of the human mitochondrial genome. Nature 290, 457–465.

Ojala, D., Montoya, J. and Attardi, G. (1981) TRNA punctuation model of RNA end processing of messenger RNA precursors. J. Biol. Chem. 266, 3131–3139.

Nagaike, T., Suzuki, T. and Ueda, T. (2008) Maturation of mammalian H/ACA box snoRNAs: PAPD5-dependent uridylation. RNA 14, 1737–1746.

Kwak, J.E., Wang, L., Ballantyne, S., Kimble, J. and Wickens, M. (2004) Nuclear surveillance and degradation of hypomodified initiator mRNAs are stabilized with polyadenylation regulated by mitochondria-normalized mitochondrial translation. Mol. Cell. Biol. 24, 7961–7973.

Barlok, C.A., Laishram, R.S. and Anderson, R.A. (2010) Nuclear poly(A) polymerases: a signaling enigma wrapped in a compartmental conundrum. Trends Cell Biol. 20, 25–35, http://dx.doi.org/10.1016/j.tcb.2009.09.009.

Bunce, M.W., Bergendahl, K. and Anderson, R.A. (2006) Nuclear P(4,5)P(2): a novel target for the PARP family. Biochem. Biophys. Acta 1761, 560–569.

Doughman, R.L., Firestone, A.J. and Anderson, R.A. (2003) Phosphatidylinositol phosphate kinases put P(4,5)P(2) in its place. J. Membr. Biol. 194, 77–89.

Gonzalez, M.L., Millman, D.L. and Anderson, R.A. (2008) CKalpha is associated with and phosphorylates star-PAP and is also required for expression of select star-PAP target messenger RNAs. J. Biol. Chem. 283, 12665–12673.

Laishram, R.S., Barlok, C.A. and Anderson, R.A. (2011) PKC isoforms alpha and epsilon regulate Star-PAP target messages by controlling Star-PAP poly(A) polymerase activity and phosphorysine stimulation. Nucleic Acids Res. 39, 7961–7973.

Newman, A. (1994) RNA splicing. Activity in the splicesome. Curr. Biol. 4, 45–54.

Tripp, R., Richly, H. and Benecke, B.J. (2003) Biochemical characterization of a U6 small nuclear RNA-specific terminal uridylyltransferase. Eur. J. Biochem. 270, 971–980.

Tripp, R., Sandrock, B. and Benecke, B.J. (1998) A highly specific terminal uridylyl transferase modifies the 3' end of U6 small nuclear RNA. Nature 409, 832–833.

Rissland, O.S. (2009) LIN-28 and the poly(U) polymerase PUP-2 regulate let-7 microRNA processing in C. elegans. Nature 497, 244–248.

Zhang, Y., Dang, A., Baliunas, S., et al. (2013) The exoribonuclease Dis3L2 defines a novel eukaryotic RNA degradation pathway. EMBO J. 32, 1855–1868.

Malecki, M., Viegas, S.C., Carnie, T., Kolik, P., Dresseire, C., Ferreira, M.G., et al. (2013) The exonobincuclease Dis3L2 defines a novel eukaryotic RNA degradation pathway. EMBO J. 32, 1842–1854.
